Publications by authors named "Adewunmi Falohun"
Background: Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) as therapy for irAEs.
Methods: We performed a retrospective multicenter study evaluating patients diagnosed with de novo irAEs or flare of pre-existing autoimmune disease following ICI and were treated with anti-IL-6R.
Article Synopsis
- The study examines the use of immune checkpoint inhibitors (ICIs) in people living with HIV (PWH) who also have cancer, highlighting their historical exclusion from trials compared to those without HIV.
- A retrospective analysis of 390 PWH treated with anti-PD-1 or anti-PD-L1 therapies shows a diversity of cancers, with a notable response rate and low toxicity profile in this population.
- The findings suggest that the safety and effectiveness of ICIs are comparable between PWH and those without HIV, indicating that PWH can benefit from these cancer treatments without increased adverse effects.
Article Synopsis
- The study aimed to compare the safety and efficacy of biologic DMARDs, specifically TNFi and IL6Ri, with conventional DMARD methotrexate (MTX) in patients with inflammatory arthritis linked to immune checkpoint inhibitors (ICI-IA).
- It included 147 patients and found that TNFi led to quicker cancer progression and faster arthritis control compared to MTX, while results for IL6Ri were less definitive.
- The conclusion suggests that while biologic DMARDs may provide faster relief from arthritis symptoms, they could also be linked to quicker cancer progression compared to traditional MTX treatment.
Immune checkpoint blockade (ICB) therapy frequently induces immune-related adverse events. To elucidate the underlying immunobiology, we performed a deep immune analysis of intestinal, colitis, and tumor tissue from ICB-treated patients with parallel studies in preclinical models. Expression of interleukin-6 (IL-6), neutrophil, and chemotactic markers was higher in colitis than in normal intestinal tissue; T helper 17 (Th17) cells were more prevalent in immune-related enterocolitis (irEC) than T helper 1 (Th1).
View Article and Find Full Text PDF